What records are connected here?
- Evidence lanes
- 3
- Source years
- 16
- Drugs@FDA applications
- 11
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsNot a single peptideBrain, nerves and sleep · Inflammation and immune
Not a single peptide: a mixture often looked up alongside peptides.
Glatiramer acetate is not a single peptide: it is a mixture of synthetic polypeptides built from four amino acids, glutamic acid, alanine, tyrosine and lysine, in fixed proportions. It is the active ingredient in Copaxone.1,3 FDA approved Copaxone in 1996, and its label covers relapsing forms of multiple sclerosis in adults.1,2 In the largest trial in the label, 1,404 people with relapsing-remitting multiple sclerosis had 34% fewer relapses over a year than on placebo. The label carries a boxed warning about life-threatening and fatal anaphylaxis.1
| Substance type | Not a single peptide. The Copaxone label states that glatiramer acetate consists of the acetate salts of synthetic polypeptides made from four amino acids, and FDA’s substance registry records it as a polymer.1,3 |
|---|---|
| What it is | Acetate salts of synthetic polypeptides made of L-glutamic acid, L-alanine, L-tyrosine and L-lysine, with an average molecular weight of 5,000 to 9,000 daltons, according to the label.1 |
| FDA status | FDA-approved. Drugs@FDA lists Copaxone, NDA 020622, with an original approval date of December 20, 1996. The label has a boxed warning about anaphylaxis.1,2 |
| Human evidence | Five placebo-controlled trials in relapsing multiple sclerosis described in the label, the largest in 1,404 people.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
The label states that glatiramer acetate consists of the acetate salts of synthetic polypeptides containing four naturally occurring amino acids, L-glutamic acid, L-alanine, L-tyrosine and L-lysine, in average molar fractions of 0.141, 0.427, 0.095 and 0.338.1
FDA’s substance registry records it as a polymer, also called copolymer-1, rather than as one defined molecule.3
In the United States it is the active ingredient of Copaxone, NDA 020622, according to Drugs@FDA.2
The label states that how it works in multiple sclerosis is not fully understood, but that it is thought to act by modifying immune processes believed to drive the disease.1
In Study 5, 1,404 people with relapsing-remitting multiple sclerosis were randomized to glatiramer acetate or placebo for 12 months; the relative risk of confirmed relapses was 34% lower with glatiramer acetate, according to the label.1
In Study 2, 251 people were followed for two years; the mean relapse rate was 1.19 with glatiramer acetate and 1.68 with placebo, a difference with a p-value of 0.055. Study 4, in 239 people, found fewer MRI lesions over nine months.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Copaxone, NDA 020622, with an original approval date of December 20, 1996.2
The Copaxone label cited here (DailyMed SPL version 36, published June 26, 2026) states that it is indicated for relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1
The label carries a boxed warning that life-threatening and fatal anaphylaxis has been reported, at any time from the first exposure to years after starting, and that it must not be used by people with a history of hypersensitivity reactions to it, including anaphylaxis.1
Exactly how it works in multiple sclerosis, which the label states is not fully understood.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Glatiramer acetate: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Glatiramer acetate are a bounded selection, not every registration or paper about Glatiramer acetate. For the years before Glatiramer acetate was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Glatiramer acetate as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Glatiramer acetate in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Copaxone for relapsing multiple sclerosis. The label describes five placebo-controlled trials; in the largest, 1,404 people had 34% fewer relapses. The label carries a boxed warning about anaphylaxis.↗↗
Status sources checked through November 16, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Copaxone for relapsing multiple sclerosis. The label describes five placebo-controlled trials; in the largest, 1,404 people had 34% fewer relapses. The label carries a boxed warning about anaphylaxis.↗↗
The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 16, 2026
ClinicalTrials.gov record NCT05344469↗Added to PeptideScanner November 17, 2026Clinical trials · added November 17, 2026
ClinicalTrials.gov record NCT05344469↗Source date November 16, 2026Regulatory · added November 17, 2026
Drugs@FDA application ANDA213382↗Source date February 11, 2026Regulatory · added November 17, 2026
Drugs@FDA application ANDA214022↗Source date February 11, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
24 of 26 selected trial records include at least one phase value; 26 of 26 include a status value in the retained structured contract.
A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”
25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091646 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.
25 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span December 20, 1996 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗
Literature metadata
PubMed lists PMID 27880972 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2016-11-24 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41705515 in Multiple sclerosis (Houndmills, Basingstoke, England) as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-02-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39406508 in Pharmacological reviews as Journal Article, Review, with publication-date metadata of 2024-10-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23424159 in Annals of neurology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-03-11 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients.↗
Literature metadata
PubMed lists PMID 25062935 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2014-07-26 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35563884 in Cells as Journal Article, Systematic Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2022-05-07 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 208468 with status AP dated 2025-05-07, and names glatiramer acetate among the application record's active ingredients.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03193866 at 2026-11-16T17:42:50.457Z. Its registry update date was 2025-04-20, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
FDA Global Substance Registration System · Official source · Source checked November 16, 2026